Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
A company-issued PR Newswire release relevant to peptide research or development. Treat claims as preliminary unless confirmed by peer-reviewed evidence or an official regulator.
Open original source ↗Collected Nov 5, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.